Abbott Laboratories (NYSE:ABT) saw an upside of 0.74% to close Monday at $108.45 after adding $0.8 on the day. The 5-day average trading volume is 4,049,420 shares of the company’s common stock. It has gained $111.25 in the past week and touched a new high 1 time within the past 5 days. An average of 4,734,045 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 4,998,226.
ABT’s 1-month performance is 1.97% or $2.10 on its low of $105.96 reached on 07/18/23. The company’s shares have touched a 52-week low of $93.25 and high of $115.83, with the stock’s rally to the 52-week high happening on 07/24/23. YTD, ABT has lost -1.22% or -$1.34 and has reached a new high 7 times. However, the current price is down -6.37% from the 52-week high price.
Insider Transactions
ABT stock investors last saw insider trading activity on Jul 27.STARKS DANIEL J (Director) most recently sold 50,000 shares at $113.76 per share on Jul 27. This transaction cost the insider $5,688,189. Director, STARKS DANIEL J, sold 50,000 shares at a price of $111.02 on May 02. Then, on May 02, EXECUTIVE VICE PRESIDENT Wainer Andrea F sold 8,226 shares at a price of $110.56 per share. This transaction amounted to $909,472.
Valuation Metrics
ABT stock has a beta of 0.67. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 4.68 while the price-to-book (PB) in the most recent quarter is 5.08, with the price to cash flow ratio at 91.50.
Abbott Laboratories’s quick ratio for the period ended June 29 was 1.20, with the current ratio over the same period at 1.60. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.39, while the total debt to equity was 0.45. In terms of profitability, the gross margin trailing 12 months is 55.20%. The trailing 12-month EBITDA margin is 26.64% while for the period ending June 29, Abbott Laboratories’s operating margin was 15.20%. The firm’s gross profit as reported stood at $24.51 billion against revenue of $43.65 billion.
Earnings Surprise
For the quarterly period ending June 29 this year, Abbott Laboratories’s cash and short-term investments amounted to $320.0 million against total debt of $16.99 billion. Net income and sales went up compared to those figures reported in the previous quarter. Net income shrunk -46.76% to $1.38 billion, while revenue of $1.32 billion was 4.15% off the previous quarter. Analysts expected ABT to announce $1.05 per share in earnings in its latest quarter, but it posted $1.08, representing a 2.90% surprise. EBITDA for the quarter stood at more than $2.34 billion. ABT stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 35.95 billion, with total debt at $16.99 billion. Shareholders hold equity totaling $1.74 billion.
Let’s look briefly at Abbott Laboratories (ABT) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 07 August was 42.53% to suggest the stock is trending Neutral, with historical volatility in this time period at 14.00%.
The stock’s 5-day moving average is $108.56, reflecting a -2.59% or -$2.88 change from its current price. ABT is currently trading +1.34% above its 20-day SMA, +10.05% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +4.24% and SMA200 by+3.31%.
Stochastic %K and %D was 16.33% and 22.04% and the average true range (ATR) pointed at 1.74. The RSI (14) points at 47.04%, while the 14-day stochastic is at 15.85% with the period’s ATR at 1.76. The stock’s 9-day MACD Oscillator is pointing at -2.52 and -3.16 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Abbott Laboratories (NYSE: ABT), Wolfe Research upgraded it to a Peer perform rating. They previously had an Underperform rating on the stock. Analysts offering their rating for ABT stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate ABT as a “sell,”, while 7 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 5 rates the stock as overweight while 13 have offered a “buy” rating.
What is ABT’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $112.00 and a high of $136.00, with their median price target at $123.00. Looking at these predictions, the average price target given by analysts is for Abbott Laboratories (ABT) stock is $124.32.
